Transcript 02/06/04 NHPF - International Society For

2007-2008 COUNCIL ACTIVITIES
Council Members
CHAIR
Jean Paul Gagnon PhD, RPh, sanofi aventis, USA
LEADERSHIP
Lieven Annemans PhD, MSc, Mman, Ghent University, Belgium
Jon Clouse MS, RPh, United Health Care, USA
Michael Drummond PhD, University of York, UK
David Eddy PhD, MD, Archimedes, Inc., USA
Joel Hay PhD, USC Dept. of Pharmaceutical Economics & Policy, USA
Kathleen N. Lohr PhD, MPhil, MA, RTI International, USA
Bryan Luce MBA, PhD United BioSource Corporation, USA
William McGhan PharmD, PhD, University of the Sciences USA
Peter J. Neumann, ScD, Tufts-New England Medical Center, USA
Jim Smeeding MBA, RPh, JestaRx Group, USA
Sean Sullivan PhD, RPh, MS, University of Washington, USA
John E. Ware, Jr. PhD, QualityMetric Inc., USA
Milton Weinstein PhD, Harvard School of Public Health, USA
Council Mission
The mission of the Health Science Policy Council is
to advise the Society on key science research and
research policy issues in pharmacoeconomics and
outcomes research.
The ISPOR Health Science Policy Council, an
advisory council to the Board of Directors, was
established May 2004 to assure that ISPOR is
addressing key research and policy issues in
pharmacoeconomics and outcomes research
Council Membership
• The ISPOR Health Science Policy Council is composed
of past ISPOR Presidents, recipients of the Avedis
Donabedian Lifetime Achievement Award and key
thought leaders selected by the Council.
 The Council can invite outcomes research experts to
serve on an ad-hoc, as-needed basis.
 The Council and the Board of Directors can invite key
thought leaders from areas that are underrepresented on the Council to assure the Council
accurately represents the interests of the ISPOR
membership
• ISPOR members interested in serving on the
Council can submit a letter of interest to the
Board of Directors
Council Work Plan
• Council members identify and discuss
issues submitted by ISPOR members
and Council members during bi-monthly
teleconferences and meetings.
• Issues approved by the Council are then
presented to the Board of Directors for
discussion and further action.
Issues Currently Under
Consideration by HSPC
• Bridging the Health Measurement Gap
• Outcomes Research in Evidence-Based
Health Care Decision-Making
• Explaining CEA to Health Care Decision
Makers & Their Clients
• Summary Measures of Population
Health
• IQWiG’s Proposed Drug Cost Benefit
Methodology
ISPOR Task Forces
Approved by Council and
Board of Directors
• Quality Improvement in Cost Effectiveness
Research (QICER) Task Force
Bill McGhan, TF Chair
• Good Research Practices Task Force on
Economic Data Transferability
Mike Drummond, TF Chair
• Drug Costs Standards Task Force
Jim Smeeding, TF Chair
New Issues
• ISPOR members are welcome to submit ideas for
development and discussion
• Each issue will be discussed and debated
• Issue authors will be recognized and informed of
issue status
• Submissions can be made via email to the
Health Science Policy Council’s ISPOR Staff
Liaison at [email protected]